SK3232000A3 - MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL - Google Patents

MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL Download PDF

Info

Publication number
SK3232000A3
SK3232000A3 SK323-2000A SK3232000A SK3232000A3 SK 3232000 A3 SK3232000 A3 SK 3232000A3 SK 3232000 A SK3232000 A SK 3232000A SK 3232000 A3 SK3232000 A3 SK 3232000A3
Authority
SK
Slovakia
Prior art keywords
cells
human
monoclonal antibody
iap
antibody
Prior art date
Application number
SK323-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Naoshi Fukushima
Shinsuke Uno
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SK3232000A3 publication Critical patent/SK3232000A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK323-2000A 1997-09-11 2000-03-07 MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL SK3232000A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11

Publications (1)

Publication Number Publication Date
SK3232000A3 true SK3232000A3 (en) 2000-09-12

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
SK323-2000A SK3232000A3 (en) 1997-09-11 2000-03-07 MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL

Country Status (14)

Country Link
US (1) US20030157100A1 (fr)
EP (1) EP1035132B1 (fr)
KR (2) KR20040106585A (fr)
CN (1) CN1198845C (fr)
AT (1) ATE395362T1 (fr)
AU (1) AU740225B2 (fr)
CA (1) CA2303072A1 (fr)
DE (1) DE69839492D1 (fr)
HU (1) HUP0003513A3 (fr)
NO (1) NO20001238L (fr)
PL (1) PL339265A1 (fr)
RU (1) RU2212413C2 (fr)
SK (1) SK3232000A3 (fr)
WO (1) WO1999012973A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721015B1 (fr) * 1993-09-03 2004-10-27 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal permettant d'induire une apoptose
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
AU2940900A (en) * 1999-03-10 2000-09-28 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
TWI242043B (en) * 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
AU2001246934A1 (en) * 2000-04-17 2001-10-30 Chugai Seiyaku Kabushiki Kaisha Agonist antibodies
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
EP1327681A4 (fr) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
CN1308447C (zh) * 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
AU1091702A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded tpo agonist antibody
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US8158385B2 (en) 2002-10-11 2012-04-17 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1609803A4 (fr) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd Anticorps modifie dirige contre cd22 et son utilisation
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
JP4637749B2 (ja) * 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
EP1927367A4 (fr) * 2005-05-18 2009-08-12 Univ Tokushima Nouvel agent pharmaceutique a base d un anticorps anti-hla
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
WO2007033221A2 (fr) * 2005-09-13 2007-03-22 The General Hospital Corporation Methodes et compositions permettant d'inhiber des reponses immunitaires
WO2008007755A1 (fr) * 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha inducteur de mort cellulaire
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
CA2711370C (fr) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Marqueurs des cellules souches de la leucemie myeloide aigue
WO2010017332A2 (fr) 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotecteurs ciblant la thrombospondine-1 et cd47
ME03512B (fr) * 2012-02-06 2020-04-20 Inhibrx Inc Anticorps anti-cd47 et leurs méthodes d'utilisation
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
CN116425875A (zh) 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
EP3529276A4 (fr) 2016-10-21 2020-06-17 Arch Oncology, Inc. Anticorps cd47 thérapeutiques
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
WO2023076511A1 (fr) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Procédés de génération de cellules
WO2024077174A1 (fr) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2025217398A1 (fr) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Procédés de culture de cellules avec milieu de culture amélioré
WO2026006604A1 (fr) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Substitution de cellules nourricières

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0721015B1 (fr) * 1993-09-03 2004-10-27 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal permettant d'induire une apoptose
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU2232597A (en) * 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
RU2212413C2 (ru) 2003-09-20
AU9002898A (en) 1999-03-29
KR20040106585A (ko) 2004-12-17
PL339265A1 (en) 2000-12-04
CA2303072A1 (fr) 1999-03-18
NO20001238L (no) 2000-05-11
EP1035132B1 (fr) 2008-05-14
US20030157100A1 (en) 2003-08-21
WO1999012973A1 (fr) 1999-03-18
HUP0003513A3 (en) 2004-05-28
HUP0003513A2 (hu) 2001-02-28
KR20010023866A (ko) 2001-03-26
DE69839492D1 (de) 2008-06-26
ATE395362T1 (de) 2008-05-15
AU740225B2 (en) 2001-11-01
EP1035132A4 (fr) 2005-02-09
EP1035132A1 (fr) 2000-09-13
CN1276798A (zh) 2000-12-13
NO20001238D0 (no) 2000-03-09
CN1198845C (zh) 2005-04-27

Similar Documents

Publication Publication Date Title
AU740225B2 (en) Monoclonal antibody inducing apoptosis
US7531643B2 (en) Monoclonal antibody inducing apoptosis
KR100795745B1 (ko) 인슐린-유사 성장 인자 ⅰ 수용체에 대한 항체 및 그의용도
Uno et al. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia
KR100919915B1 (ko) Ｎｋｇ２ｄ의 조절
US6579692B1 (en) Method of screening apoptosis inducing substances
JP2023546743A (ja) 抗ｃｄ７３抗体及びその使用
CN111978402A (zh) 新型cldn18.2结合分子
CN111978403A (zh) 新型cldn18.2结合分子
JP3568398B2 (ja) アポトーシスを誘起するモノクローナル抗体
CZ2000907A3 (cs) Monoklonální protilátka indukující apoptózu
HK1030785A (en) Monoclonal antibody inducing apoptosis
Wallén‐Öhman et al. A cell surface antigen (BAL) defined by a mouse monoclonal antibody inducing apoptosis in a human lymphocytic leukemia cell line
HK1030954A (en) Monoclonal antibody inducing apoptosis
HK40032484A (en) Novel cldn18.2 binding molecule